We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current CRL market cap is 9.52B. The company's latest EPS is USD 9.2816 and P/E is 20.06.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 1.03B | 1.01B | 1.01B | 1.03B | 1.01B |
Operating Income | 151.5M | 132.92M | 133.94M | 163.71M | 97.39M |
Net Income | 87.39M | 187.08M | 67.33M | 89.99M | 79.38M |
Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 2.62B | 2.92B | 3.54B | 3.98B | 4.13B |
Operating Income | 351.15M | 432.73M | 589.86M | 650.98M | 617.26M |
Net Income | 252.02M | 364.3M | 390.98M | 486.23M | 474.62M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 7.61B | 8.2B | 8.15B | 7.95B | 8B |
Total Liabilities | 4.26B | 4.54B | 4.45B | 4.18B | 4.18B |
Total Equity | 3.31B | 3.6B | 3.65B | 3.73B | 3.79B |
Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 4.69B | 5.49B | 7.02B | 7.6B | 8.2B |
Total Liabilities | 3.03B | 3.35B | 4.43B | 4.58B | 4.54B |
Total Equity | 1.64B | 2.12B | 2.54B | 2.98B | 3.6B |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 462.96M | 683.9M | 129.89M | 323.42M | 575.22M |
Investing | -324.78M | -563.16M | -85.79M | -147.66M | -168.98M |
Financing | -209.09M | -85.52M | 18.35M | -267.51M | -475.05M |
Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 480.94M | 546.58M | 760.8M | 619.64M | 683.9M |
Investing | -681.5M | -601.54M | -1.44B | -607.92M | -563.16M |
Financing | 231.94M | 47.25M | 672.6M | -42.4M | -85.52M |
Market Cap | 9.52B |
Price to Earnings Ratio | 20.06 |
Price to Sales Ratio | 2.31 |
Price to Cash Ratio | 34.41 |
Price to Book Ratio | 2.6 |
Dividend Yield | - |
Shares Outstanding | 51.14M |
Average Volume (1 week) | 568.45k |
Average Volume (1 Month) | 544.13k |
52 Week Change | -21.93% |
52 Week High | 275.00 |
52 Week Low | 176.48 |
Spread (Intraday) | 34.6 (15.73%) |
Company Name | Charles River Laboratories International Inc |
Address |
251 little falls drive wilmington, delaware 19808 |
Website | https://www.criver.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions